In vitro activation of cytotoxic T-lymphocytes by hTERT-pulsed dendritic cells

References

• Banchereau, J., and Steinman, R. M. 1998. Dendritic cells and the control of immunity. Nature 392:245–252.
   PubMed Web of Science ®Google Scholar
• Becker, C., Pohla, H., Frankenberger, B., Schuler, T., Assenmacher, M., Schendel, D. J., and Blankenstein, T. 2001. Adoptive tumor therapy with T-lymphocytes enriched through an IFNγ capture assay. Nat. Med. 7:1159–1162.
   PubMed Web of Science ®Google Scholar
• Bendandi, M., Gocke, C. D., Kobrin, C. B., Benko, F. A., Sternas, L. A., Pennington, R., Watson, T. M., Reynolds, C. W., Gause, B. L., Duffey, P. L., Jaffe, E. S., Creekmore, S. P., Longo, D. L., and Kwak, L. W. 1999. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med. 5:1171–1177.
   PubMed Web of Science ®Google Scholar
• Blackburn, E. H. 1991. Structure and function of telomeres. Nature 350:569–573.
   PubMed Web of Science ®Google Scholar
• Brossart, P., Goldrath, A. W., Butz, E. A., Martin, S., and Bevan, M. J. 1997. Adenovirus mediated delivery of antigenic epitopes into DC by a means of CTL induction. J. Immunol. 158:3270–3276.
   PubMed Web of Science ®Google Scholar
• Brossart, P., Wirths, S., Stuhler, G., Reichardt, V. L., Kanz, L., and Brugger, W. 2000. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96:3102–3108.
   PubMed Web of Science ®Google Scholar
• Brossart, P., Schneider, A., Dill, P., Schammann, T., Grünebach, F., Wirths, S., Kanz, L., Bühring, H. J., and Brugger, W. 2001. The epithelial tumor antigen HTERT is expressed in hematological malignancies and is recognized by HTERT-specific cytotoxic T-lymphocytes. Cancer Res. 61:6846–6850.
   PubMed Web of Science ®Google Scholar
• Bryant, P., and Ploegh, H. 2004. Class II MHC peptide loading by the professionals. Curr. Opin. Immunol. 16:96–102.
   PubMed Web of Science ®Google Scholar
• Büchler, T., Hájek, R., Bourková, L., Kovarova, L., Musilova, R., Bulikova, A., Doubek, M., Svobodnik, A., Mareschova, I., Vanova, P., Tuzova, E., Vidlakova, P., Vorlicek, J., and Penka, M. 2003. Generation of antigen-loaded cells in a serum-free medium using different cytokine combinations. Vaccine 21:877–882.
   PubMed Web of Science ®Google Scholar
• Chang, L., Gusewitch, G. A., Chritton, D. B., Folz, J. C., Lebeck, L. K., and Nehlsen-Cannarella, S. L. 1993. Rapid flow cytometric assay for the assessment of natural killer cell activity. J. Immunol. Meth. 166:45–54.
   PubMed Web of Science ®Google Scholar
• Danet-Desnoyers, G. A., Luongo, J. L., Bonnet, D. A., Domchek, S. M., and Vonderheide, R. H. 2005. Telomerase vaccination has no detectable effect on SCID-repopulating and colony-forming activities in the bone marrow of cancer patients. Exp. Hematol. 33:1275–1280.
   PubMed Web of Science ®Google Scholar
• De Lange, T. 1994. Activation of telomerase in a human tumor. Proc. Natl. Acad. Sci. USA 91:2882–2885.
   PubMed Web of Science ®Google Scholar
• Filaci, G., Fravega, M., Setti, M., Traverso, P., Millo, E., Fenoglio, D., Negrini, S., Ferrera, F., Romagnoli, A., Basso, M., Contini, P., Rizzi, M., Ghio, M., Benatti, U., Damonte, G., Ravetti, J. L., Carmignani, G., Zanetti, M., and Indiveri, F. 2006. Frequency of telomerase-specific CD8+ T-lymphocytes in patients with cancer. Blood 107:1505–1512.
   PubMed Web of Science ®Google Scholar
• Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., and Levy, R. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2:52–58.
   PubMed Web of Science ®Google Scholar
• Huo, L. F., Tang, J. W., Huang, J. J., Huang, P. T., Huang, C. F., Kung, H. F., and Lin, M. C. 2006. Cancer immunotherapy targeting the telomerase reverse transcriptase. Cell. Mol. Immunol. 3:1–11.
   PubMed Web of Science ®Google Scholar
• Jarnjak-Jankovic, S., Hammerstad, H., Saebøe-Larssen, S., Kvalheim, G., and Gaudernack, G. 2007. A full-scale comparative study of methods for generation of functional dendritic cells for use as cancer vaccines. BMC Cancer 7:119.
   PubMed Web of Science ®Google Scholar
• Jaruga, E., Skierski, J., Radziszewska, E., and Sikora, E. 2000. Proliferation and apoptosis of human T-cells during replicative senescence—a critical approach. Acta Biochim. Pol. 47:293–300.
   PubMed Web of Science ®Google Scholar
• Kalamasz, D., Long, S. A., Taniguchi, R., Buckner, J. H., Berenson, R. J., and Bonyhadi, M. 2004. Optimization of human T-cell expansion ex vivo using magnetic beads conjugated with anti-CD3 and anti-CD28 antibodies. J. Immunother. 27:405–418.
   PubMed Web of Science ®Google Scholar
• Keith, W. N., Bilsland, A., Evans, J. T. R., and Glasspool, R. M. 2002. Telomerase-directed molecular therapeutics. Exp. Rev. Mol. Med. 4(10):1–25. http://www.expertreviews.org.
   PubMedGoogle Scholar
• Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L., Coviello, G. M., Wright, W. E., Weinrich, S. L., and Shay, J. W. 1994. Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011–2015.
   PubMed Web of Science ®Google Scholar
• Kuehl, W. M., and Bergsagel, P. L. 2002. Multiple myeloma: Evolving genetic events and host interactions. Nat. Rev. Cancer 2:175–187.
   PubMed Web of Science ®Google Scholar
• Martín-Ayuso, M., Almeida, J., Pérez-Andrés, M., Cuello, R., Galende, J., González-Fraile, M. I., Martín-Nuñez, G., Ortega, F., Rodríguez, M. J., San Miguel, J. F., and Orfao, A. 2008. Peripheral blood dendritic cell subsets from patients with monoclonal gammopathies show an abnormal distribution and are functionally impaired. Oncologist 13:82–92.
   PubMed Web of Science ®Google Scholar
• Minev, B., Hipp, J., Firat, H., Schmidt, J. D., Langlade-Demoyen, P., and Zanetti, M. 2000. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc. Natl. Acad. Sci. USA 97:4796–4801.
   PubMed Web of Science ®Google Scholar
• Morin, G. B. 1989. Human telomerase terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 59:521–529.
   PubMed Web of Science ®Google Scholar
• Nair, S. K., Heiser, A., Boczkowski, D., Majumdar, A., Naoe, M., Lebkowski, J. S., Vieweg, J., and Gilboa, E. 2000. Induction of cytotoxic T-cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA-transfected dendritic cells. Nat. Med. 6:1011–1017.
   PubMed Web of Science ®Google Scholar
• Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., and Schadendorf, D. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:328–332.
   PubMed Web of Science ®Google Scholar
• Ocadlikova, D., Zahradova, L., Kovarova, L., Penka, M., Zaloudik, J., Buchler, T., Hajek, R., and Michalek, J. 2006. Isolation and expansion of allogeneic myeloma-specific interferon-gamma producing T-cells for adoptive immunotherapy. Med. Oncol. 23:377–384.
   PubMed Web of Science ®Google Scholar
• Paglia, P., Chiodoni, C., Rodolfo, M., and Colombo, M. P. 1996. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T-lymphocytes against tumor antigen in vivo. J. Exp. Med. 183:317–322.
   PubMed Web of Science ®Google Scholar
• Porgador, A., and Gilboa, E. 1995. Bone-marrow-generated dendritic cells pulsed with a Class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. Exp. Med. 182:255–260.
   PubMed Web of Science ®Google Scholar
• Pratt, G., Goodyear, O., and Moss, P. 2007. Immunodeficiency and immunotherapy in multiple myeloma. Br. J. Haematol. 138:563–579.
   PubMed Web of Science ®Google Scholar
• Shay, J. W., Zou, Y., Hiyama, E., and Wright, W. E. 2001. Telomerase and cancer. Human Mol. Genet. 10:677–685.
   PubMed Web of Science ®Google Scholar
• Steinman, R. M. 1991. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9:271–296.
   PubMed Web of Science ®Google Scholar
• Thurner, B., Haendle, I., Roder, C., Dieckmann, D., Keikavoussi, P., Jonuleit, H., Bender, A., Maczek, C., Schreiner, D., von den Driesch, P., Brocker, E. B., Steinman, R. M., Enk, A., Kampgen, E., and Schuler, G. 1999. Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T-cells and induces regression of some metastases in advanced Stage IV melanoma. J. Exp. Med. 190:1669–1678.
   PubMed Web of Science ®Google Scholar
• Timmerman, J. M., and Levy R. 1999. Dendritic cell vaccines for cancer immunotherapy. Annu. Rev. Med. 50:507–529.
   PubMed Web of Science ®Google Scholar
• Vonderheide, R. H., Hahn, W. C., Schultze, J. L., Nadler, L. M. 1999. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T-lymphocytes. Immunity 10:673–690.
   PubMed Web of Science ®Google Scholar
• Zitvogel, L., Mayordomo, J. I., Tjandrawan, T., DeLeo, A. B., Clarke, M. R., Lotze, M. T., and Storkus, W. J. 1996. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T-cells, B7 co-stimulation, and T-helper cell 1-associated cytokines. J. Exp. Med. 183:87–97.
   PubMed Web of Science ®Google Scholar
• Zobywalski, A., Javorovic, M., Frankenberger, B., Pohla, H., Kremmer, E., Bigalke, I., and Schendel, D. J. 2007. Generation of clinical grade dendritic cells with capacity to produce biologically-active IL-12p70. J. Transl. Med. 5:18.
   PubMed Web of Science ®Google Scholar